Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL12 2022 | Recent updates in HL research & the importance of improving treatment for elderly & frail patients

Ninja Övergaard • 19 Oct 2022
ISHL12 2022
Hodgkin Lymphoma Lymphoma Dacarbazine Doxorubicin Vinblastine

Ninja Övergaard, PhD, Uppsala University, Uppsala, Sweden, briefly comments on recent developments in Hodgkin lymphoma (HL) research, highlighting that a growing number of studies are investigating HL in elderly and frail patients, and that promising novel agents are being explored. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ninja Övergaard

4:42
Comparing ABVD, AVD & CHOP chemotherapy regimens in older patients with classical HL
Ninja Övergaard • 19 Oct 2022

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:39
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
Wendy Osborne • 22 Apr 2024
1:24
Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi • 24 Apr 2024
The content of VJHemOnc is intended for healthcare professionals